Metyrosine Capsules

Manufacturer
Oceanside Pharmaceuticals | Bausch Health Companies Inc.
Effective date
2021-07-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
4
Source
full-release
Hydrated at
2026-05-31 20:37:49

Label at a glance#

ProductMetyrosine
Active ingredientmetyrosine
Label structure11 sections

Indications and uses

Metyrosine is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of patients with malignant pheochromocytoma Metyrosine is not recommended for the control of essential hypertension.

Dosage and administration

The recommended initial dosage of Metyrosine for adults and children 12 years of age and older is 250 mg orally four times daily. This may be increased by 250 mg to 500 mg every day to a maximum of 4 g/day in divided doses. When used for preoperative preparation, the optimally effective dosage of Metyrosine should be given for at least five to seven days. Optimally effective dosages of Metyrosine usually are betwe...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Metyrosine is (–)-α-methyl-L-tyrosine or (α-MPT). It has the following structural formula:

DESCRIPTION
DESCRIPTION

Metyrosine is a white to off-white, crystalline compound of molecular weight 195.22. It is very slightly soluble in water, acetone, and methanol, and insoluble in chloroform and benzene. It is soluble in acidic aqueous solutions. It is also soluble in alkaline aqueous solutions, but is subject to oxidative degradation under these conditions.

Metyrosine is supplied as capsules for oral administration. Each capsule contains 250 mg metyrosine.

Inactive ingredients are colloidal silicon dioxide, gelatin, hydroxypropyl cellulose, magnesium stearate, titanium dioxide, FD&C Blue 2 and edible black ink.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of 1 to 4 grams of Metyrosine per day has reduced catecholamine biosynthesis from about 35% to 80% as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after Metyrosine is discontinued. In some patients the total excretion of catecholamines and catecholamine metabolites may be lowered to normal or near normal levels (less than 10 mg/24 hours). In most patients, the duration of treatment has been two to eight weeks, but several patients have received Metyrosine for periods of 1 to 10 years.

Most patients with pheochromocytoma treated with Metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with Metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Metyrosine is well absorbed from the gastrointestinal tract. From 53% to 88% (mean 69%) was recovered in the urine as unchanged drug following maintenance oral doses of 600 to 4000 mg/24 hours in patients with pheochromocytoma or essential hypertension. Less than 1% of the dose was recovered as catechol metabolites. These metabolites are probably not present in sufficient amounts to contribute to the biochemical effects of metyrosine. The quantities excreted, however, are sufficient to interfere with accurate determination of urinary catecholamines determined by routine techniques.

Plasma half-life of metyrosine determined over an 8-hour period after single oral doses was 3-3.7 hours in three patients.

For further information, refer to: Sjoerdsma A, Engelman K, Waldman TA, Cooperman LH, Hammond WG. Pheochromocytoma: Current Concepts of Diagnosis and Treatment: Combined Clinical Staff Conference at the National Institutes of Health. Ann Intern Med. 1966;65:1302-1326.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Metyrosine is indicated in the treatment of patients with pheochromocytoma for:

1. Preoperative preparation of patients for surgery

2. Management of patients when surgery is contraindicated

3. Chronic treatment of patients with malignant pheochromocytoma

Metyrosine is not recommended for the control of essential hypertension.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Metyrosine is contraindicated in persons known to be hypersensitive to this compound.

WARNINGS

WARNINGS SECTION

Maintain Fluid Volume During and After Surgery

SPL UNCLASSIFIED SECTION

When Metyrosine is used preoperatively, alone or especially in combination with alpha-adrenergic blocking drugs, adequate intravascular volume must be maintained intraoperatively (especially after tumor removal) and postoperatively to avoid hypotension and decreased perfusion of vital organs resulting from vasodilatation and expanded volume capacity. Following tumor removal, large volumes of plasma may be needed to maintain blood pressure and central venous pressure within the normal range.

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. During surgery, patients should have continuous monitoring of blood pressure and electrocardiogram.

Intraoperative Effects

SPL UNCLASSIFIED SECTION

While the preoperative use of Metyrosine in patients with pheochromocytoma is thought to decrease intraoperative problems with blood pressure control, Metyrosine does not eliminate the danger of hypertensive crises or arrhythmias during manipulation of the tumor, and the alpha-adrenergic blocking drug, phentolamine, may be needed.

PRECAUTIONS

PRECAUTIONS SECTION

General

SPL UNCLASSIFIED SECTION

Metyrosine Crystalluria: Crystalluria and urolithiasis have been found in dogs treated with Metyrosine at doses similar to those used in humans, and crystalluria has also been observed in a few patients. To minimize the risk of crystalluria, patients should...

SPL UNCLASSIFIED SECTION

Relatively Little Data Regarding Long-Term Use: The total human experience with the drug is quite limited and few patients have been studied long term.

SPL UNCLASSIFIED SECTION

Chronic animal studies have not been carried out. Therefore, suitable laboratory tests should be carried out periodically in patients requiring prolonged use of Metyrosine and caution should be observed in patients with impaired hepatic or renal function.

SPL UNCLASSIFIED SECTION

Information for Patients

SPL UNCLASSIFIED SECTION

When receiving Metyrosine, patients should be warned about engaging in activities requiring mental alertness and motor coordination, such as driving a motor vehicle or operating machinery. Metyrosine may have additive sedative effects with alcohol and other CNS depressants, e.g., hypnotics, sedatives, and tranquilizers.

Patients should be advised to maintain a liberal fluid intake. (See PRECAUTIONS,General.)

Drug Interactions

SPL UNCLASSIFIED SECTION

Caution should be observed in administering Metyrosine to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.

Concurrent use of Metyrosine with alcohol or other CNS depressants can increase their sedative effects. (See WARNINGS and PRECAUTIONS,Information for Patients.)

Laboratory Test Interference

SPL UNCLASSIFIED SECTION

Spurious increases in urinary catecholamines may be observed in patients receiving Metyrosine due to the presence of metabolites of the drug.

Carcinogenesis, Mutagenesis, Impairment of Fertility

SPL UNCLASSIFIED SECTION

Long-term carcinogenic studies in animals and studies on mutagenesis and impairment of fertility have not been performed with metyrosine.

Pregnancy

SPL UNCLASSIFIED SECTION

Pregnancy: Animal reproduction studies have not been conducted with Metyrosine. It is also not known whether Metyrosine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Metyrosine should be given to a pregnant ...

SPL UNCLASSIFIED SECTION

Nursing Mothers

SPL UNCLASSIFIED SECTION

It is not known whether Metyrosine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Metyrosine is administered to a nursing woman.

Pediatric Use

SPL UNCLASSIFIED SECTION

Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

Geriatric Use

SPL UNCLASSIFIED SECTION

Clinical studies of Metyrosine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Central Nervous System

SPL UNCLASSIFIED SECTION

Sedation: The most common adverse reaction to Metyrosine is moderate to severe sedation, which has been observed in almost all patients. It occurs at both low and high dosages. Sedative effects begin within the first 24 hours of therapy, are maximal after t...

SPL UNCLASSIFIED SECTION

Sedation usually is not obvious after one week unless the dosage is increased, but at dosages greater than 2000 mg/day some degree of sedation or fatigue may persist.

SPL UNCLASSIFIED SECTION

In most patients who experience sedation, temporary changes in sleep pattern occur following withdrawal of the drug. Changes consist of insomnia that may last for two or three days and feelings of increased alertness and ambition. Even patients who do not experience sedation while on Metyrosine may report symptoms of psychic stimulation when the drug is discontinued.

Extrapyramidal Signs: Extrapyramidal signs such as drooling, speech difficulty, and tremor have been reported in approximately 10% of patients. These occasionally have been accompanied by trismus and frank parkinsonism.

SPL UNCLASSIFIED SECTION

Anxiety and Psychic Disturbances: Anxiety and psychic disturbances such as depression, hallucinations, disorientation, and confusion may occur. These effects seem to be dose-dependent and may disappear with reduction of dosage.

SPL UNCLASSIFIED SECTION

Diarrhea

SPL UNCLASSIFIED SECTION

Diarrhea occurs in about 10% of patients and may be severe. Anti-diarrheal agents may be required if continuation of Metyrosine is necessary.

Miscellaneous

SPL UNCLASSIFIED SECTION

Infrequently, slight swelling of the breast, galactorrhea, nasal stuffiness, decreased salivation, dry mouth, headache, nausea, vomiting, abdominal pain, and impotence or failure of ejaculation may occur. Crystalluria (see PRECAUTIONS) and transient dysuria and hematuria have been observed in a few patients. Hematologic disorders (including eosinophilia, anemia, thrombocytopenia, and thrombocytosis), increased SGOT levels, peripheral edema, and hypersensitivity reactions such as urticaria and pharyngeal edema have been reported rarely.

To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Signs of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages.

At doses exceeding 2000 mg/day, some degree of sedation or feeling of fatigue may persist. Doses of 2000-4000 mg/day can result in anxiety or agitated depression, neuromuscular effects (including fine tremor of the hands, gross tremor of the trunk, tightening of the jaw with trismus), diarrhea, and decreased salivation with dry mouth.

Reduction of drug dose or cessation of treatment results in the disappearance of these symptoms.

The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat, respectively.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The recommended initial dosage of Metyrosine for adults and children 12 years of age and older is 250 mg orally four times daily. This may be increased by 250 mg to 500 mg every day to a maximum of 4 g/day in divided doses. When used for preoperative preparation, the optimally effective dosage of Metyrosine should be given for at least five to seven days.

Optimally effective dosages of Metyrosine usually are between 2 and 3 g/day, and the dose should be titrated by monitoring clinical symptoms and catecholamine excretion. In patients who are hypertensive, dosage should be titrated to achieve normalization of blood pressure and control of clinical symptoms. In patients who are usually normotensive, dosage should be titrated to the amount that will reduce urinary metanephrines and/or vanillylmandelic acid by 50% or more.

If patients are not adequately controlled by the use of Metyrosine, an alpha-adrenergic blocking agent (phenoxybenzamine) should be added.

Use of Metyrosine in children under 12 years of age has been limited and a dosage schedule for this age group cannot be given.

HOW SUPPLIED

HOW SUPPLIED SECTION

Metyrosine Capsules 250 mg are blue opaque capsules imprinted with “ATON/305” on body, and “DEMSER” on cap, filled with white to off-white granular free-flowing powder. They are supplied as follows:

  • NDC 68682-310-01   bottles of 100

Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense in a well-closed container.

Distributed by:

Oceanside Pharmaceuticals, a division of Bausch Health US, LLC

Bridgewater, NJ 08807 USA

Manufactured by:

Bausch Health Companies Inc.

Steinbach, MB R5G 1Z7, Canada

DEMSER is a trademark of Bausch Health Companies Inc. or its affiliates.

© 2021 Bausch Health Companies Inc. or its affiliates

Rev. 07/2021                                                                                                9744301 20003161

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 250 mg Capsule Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68682-310-01

Rx only

METYROSINE

CAPSULES

250 mg

Each capsule contains
250 mg metyrosine

100 Capsules

OCEANSIDE PHARMACEUTICALS

label
label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
197980metyroSINE 250 MG Oral CapsulePSN4
197980metyrosine 250 MG Oral CapsuleSCD4

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
METYROSINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
c854e70c-e05b-1969-e1ff-89d3d09d1b16Product name420260122

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68682-310-01Metyrosine100 in 1 BOTTLECAPSULE1004

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68682-310METYROSINE CAPSULE [OCEANSIDE PHARMACEUTICALS]4Current NDC, Legacy NDC, 1 package rows20210915_46612725-bee0-4125-b8b5-9fed9c003ed4.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
68682-31068682-310-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N017871-001DEMSERMETYROSINE250MGCAPSULE / ORALABRLD, RS, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N017871-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N017871-001DEMSER250MGCAPSULE / ORALRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N017871-001DEMSER250MGCAPSULE / ORALABRLD, RS, Approved before 19823bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N017871-001AB1d4dbc9d85df4…
2026-10-15 13:18:302026-09N017871-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08N017871-001AB184e616aacf4f…
2026-08-18 06:07:402026-07N017871-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N017871-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N017871-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08N017871-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N017871-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N017871-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N017871-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N017871-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N017871-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N017871-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N017871-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N017871-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N017871-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N017871-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N017871-001AB18072bd15b7f6…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N017871-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03N017871-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N017871-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N017871-001AB1c0c555d07b60…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N017871-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N017871-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N017871-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N017871-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N017871-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N017871-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N017871-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05N017871-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01N017871-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N017871-001AB13a93d1ddd44b…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N017871-001AB1a50c72e98297…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
MetyrosineMETYROSINEOceanside Pharmaceuticals46612725-bee0-4125-b8b5-9fed9c003ed42021-07-01Warnings, Adverse reactionsExact identifier
ndc (package): 68682-310-01
ndc (product): 68682-310
ndc11 (package): 68682031001
spl id: e61c29ce-16b2-415c-b203-28bc9d45bb5f
spl set id: 46612725-bee0-4125-b8b5-9fed9c003ed4

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.